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Characterization of novel SLC6A8 variants with the
use of splice-site analysis tools and implementation
of a newly developed LOVD database
Ofir T Betsalel1, Efraim H Rosenberg1,2, Ligia S Almeida1,3, Tjitske Kleefstra4, Charles E Schwartz5,
Vassili Valayannopoulos6, Omar Abdul-Rahman7, Nicola Poplawski8, Laura Vilarinho3, Philipp Wolf9,
Johan T den Dunnen10, Cornelis Jakobs1 and Gajja S Salomons*,1
The X-linked creatine transporter defect is caused by mutations in the SLC6A8 gene. Until now, 66 synonymous and intronic
variants in SLC6A8 were detected in our laboratory. To gain more insight in the effect of the detected variants, we applied five
free web-based splice-site analysis tools to 25 published variants that were stratified as (non-)disease causing. All were correctly
predicted to have no effect (n¼18) or to cause erroneous splicing (n¼7), with the exception of a pathogenic de novo 24bp
intronic deletion. Second, 41 unclassified variants, including 28 novel, were subjected to analysis by these tools. At least four
splice-site analysis tools predicted that three of the variants would affect splicing as the mutations disrupted the canonical
splice site. Urinary creatine/creatinine and brain MRS confirmed creatine transporter deficiency in five patients (four families),
including one female. Another variant was predicted to moderately affect splicing by all five tools. However, transient
transfection of a minigene containing the variant in a partial SLC6A8 segment showed no splicing errors, and thus was finally
classified as non-disease causing. This study shows that splice tools are useful for the characterization of the majority
of variants, but also illustrates that the actual effect can be misclassified in rare occasions. Therefore, further laboratory
studies should be considered before final conclusions on the disease-causing nature are drawn. To provide an accessible
database, the 109 currently known SLC6A8 variants, including 35 novel ones, are included in a newly developed
LOVD DNA variation database.
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INTRODUCTION
In 2001, the X-linked mental retardation (XLMR) syndrome, SLC6A8
deficiency, was identified because of a creatine deficiency in the brain
caused by mutations in the creatine transporter (SLC6A8) gene (MIM
300036). SLC6A8 has been mapped to Xq281 and is a member of the
solute-carrier family 6 (neurotransmitter transporters). The clinical
presentation of males affected with SLC6A8 deficiency is mental
retardation (MR), expressive speech and language delay, epilepsy,
developmental delay and autistic behavior. Laboratory hallmarks
include a reduction of the creatine signal in the proton magnetic
resonance spectroscopy (H-MRS) of the brain, an increased urinary
creatine/creatinine ratio and impaired creatine uptake in cultured
fibroblasts. In female carriers, learning disabilities of varying degrees
have been noted. Two studies of males with XLMR estimated the
prevalence of SLC6A8 deficiency to be 2.1% (CI: 0.44–3.76)2 and 1.5%
(CI: 0–4.46).3 A third study of males with MR revealed a prevalence of
0.8% (CI: 0.02–1.7%).4 Within the last decade many novel variants
in the SLC6A8 gene have been detected. These variants are difficult
to classify as pathogenic or non-disease causing because the variants
are either located in the coding region, but are synonymous, or are
found in the intronic regions. However, such variants may affect
proper splicing and are potentially pathogenic.5 We therefore not only
tested if such variants could be properly analyzed by studying
previously classified variants, but also subjected 28 novel variants to
these tools. Moreover, to facilitate worldwide diagnostic and research
laboratories interested in the SLC6A8 gene, we developed a novel
LOVD database (http://www.LOVD.nl/SLC6A8), which includes
clinically and genetically relevant data.
MATERIALS AND METHODS
Subjects
In our diagnostic unit, a total of 1900 patients with a differential diagnosis
of SLC6A8 deficiency were analyzed by DNA sequence analysis. This resulted
in the detection of 66 individuals with intronic or synonymous variants
(including 28 novel). These variants are addressed in this study. Also,
five novel patients affected with SLC6A8 deficiency are reported.
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Methods
PCR of exon 1–13 of SLC6A8 (NM_005629.1). Exon 2 to 13 and flanking
intronic sequences of SLC6A8 were amplified using HotStarTaq Polymerase
(Qiagen, Valencia, CA, USA). Amplification consisted of an initial denaturation
step at 95 1C for 15min, followed by 38 cycles of 94 1C for 45 s, 66 1C for 45 s
and 72 1C for 80 s. For the amplification of exon 1 and its flanking sequences,
Takara LATaq (Takara Bio Inc., Otsu, Shiga, Japan) Polymerase was used. After
an initial denaturing step for 1min at 94 1C, amplification was allowed in 35
cycles composed of 95 1C for 30 s, 66 1C for 30 s and 72 1C for 80 s.
RT-PCR analysis of SLC6A8 cDNAs and minigenes. RNA was isolated
from lymphoblasts or fibroblasts using the SV RNA kit (Promega, Madison,
WI, USA) or from PAX blood tubes (Qiagen). cDNA was synthesized from
isolated RNA using Omniscript Reverse Transcriptase (Qiagen) according to
the manufacturer’s instructions. RT-PCR was performed using cDNA primers
designed for the exons of interest of the SLC6A8 gene. To rule out possible
amplification of genomic DNA, RT-PCR for each RNA was also performed
without reverse transcriptase.
Construction and transfection of the minigenes. Owing to the large size of
the SLC6A8 gene and its highly GC-rich 5¢region, we only cloned the region
of interest of the SLC6A8 gene. As templates for the PCR, the patients’ and a
wild-type genomic DNAs were used. The fragment, covering exons 3–7
including 53 and 55 nucleotides of the flanking 5¢ and 3¢ intronic regions
respectively, was amplified with forward primer 5¢-CCGGAATTCGTAAAACG
ACGGCCAGCAGGGGGAGGTGGCCAGGG-3¢ containing an EcoR1 site and
reverse primer 5¢-GCGTCGACCAGGAAACAGCTATGACATGCATCTGGGT
AGCACTC-3¢ with a SalI restriction site for cloning into the pBABE-puro
plasmid. The fragment was amplified using Takara LA Taq (Takara Bio Inc.),
cloned into the TOPO-TA (Invitrogen, Breda, The Netherlands) vector and
either wild-type or mutant sequence was confirmed by sequencing. For the
construction of the positive control (ie, c.777+2T4A), site directed muta-
genesis was performed on the TOPO vector containing the wild-type fragment
with forward primer 5¢-AAATCCACGGGAAAGGAACCACTAGAGGCATGC-3¢
and reverse 5¢-GCATGCCTCTAGTGGTTCCTTTCCCGTGGATTT-3¢. Presence
of the desired mutation and absence of PCR-artifacts were confirmed by
sequencing of the complete fragments. After digestion with EcoR1 and Sal1,
the inserts were sub cloned into the pBABE-puro plasmid.
Minigene constructs were transiently transfected into SLC6A8-deficient
primary fibroblasts. With the use of polyethylenimine (PEI), 25mg of construct,
in a ratio of 3:1 (PEI:DNA), was transfected in fibroblasts grown to 70%
confluence in a 75 cm2 culture disc. After 48h, cells were harvested.
DNA sequence analysis. Sequence analysis was performed using BigDye v3.1
terminator and an ABI 3130xl (Applied Biosystems, Nieuwerkerk aan de IJssel,
The Netherlands). The obtained sequences were analyzed using the Mutation
Surveyor software package (Softgenetics, State College, PA, USA).
Analysis of amplicons with DHPLC. For DHPLC analysis, optimal hetero-
duplex formation was realized by denaturing PCR products at 95 1C for 5min
and gradual cooling to 25 1C over a period of 60min. Subsequently, 5ml of the
heteroduplex/homoduplex mixture was loaded on a WAVE 3500HT DNA
fragment analysis system (Transgenomic, Omaha, NE, USA). Elution of the
PS-DVB DNAsep column (Transgenomic) was performed in high-throughput
mode with a linear gradient of increasing acetonitril (ACN) concentration with
a runtime of 3min and a constant flow rate of 1.5ml/min. Gradient was
realized with the use of buffer A (0.1M triethylammonium acetate (TEAA)
and 0.025% ACN) and buffer B (0.1M TEAA and 25% ACN). Navigator 2.0
software (Transgenomic) was used to calculate the ratio of buffer A and B
during the gradient, as well as the optimal partially denaturing temperature
(Tm) for the amplicon. The Tm of this amplicon was determined as 64 1C.
In silico analysis. The analysis of splicing efficiencies in the normal and
mutant sequences was carried out using the following five splice-site analysis tools,
which are commonly used in diagnostic laboratories: the Berkeley Drosophila
Genome Project6 (http://www.fruitfly.org/seq_tools/splice.html), Netgene27
(http://www.cbs.dtu.dk/services/NetGene2/), Splice Predictor8 (http://deepc2.
psi.iastate.edu/cgi-bin/sp.cgi), GenscanW9 (http://genes.mit.edu/GENSCAN.html)
and FSplice (http://linux1.softberry.com/berry.phtml?topic¼fsplice&group¼
programs&subgroup¼gfind). The parameters used for analysis were the default
settings of all tools.
LOVD database. The target of the LOVD database is to include all published
and unpublished mutations and variants. It is localized at a server in Leiden,
The Netherlands, which can be reached by the following URL http://
www.LOVD.nl/SLC6A8 or through the Variation Databases page of the Human
Genome Variation Society (HGVS, www.HGVS.org/). The SLC6A8-specific
database has been developed with the recently described LOVD software,10
which is in agreement with the HGVS guidelines.11 All variants are checked and
approved by Mutalyzer.12 So far 38 pathogenic mutations have been reported in
44 male patients affected with SLC6A8 deficiency.
RESULTS
Validation of splice-site analysis using previously reported variants
We analyzed seven pathogenic mutations (Table 1) detected in patients
affected with SLC6A8 deficiency by applying five splice-site analysis
tools (see methods). In six out of seven pathogenic mutations at least
four of the five tools predicted a reduced recognition of the splice sites,
varying with a reduction of the probability score between 9 and 100%.
Three mutations had significant reduction scores of499% in four of
the five tools, whereas three other variants had reduction of their
scores in a much lower range. One mutation, c.1392+24_1393-30del,
reducing the intron from 76 to 52 bp, was not recognized by all the
tools. Although analysis of this mutation with Splice Predictor resulted
in the loss of both rho and gamma values, this was not ascribed to the
mutation itself but to Splice Predictor’s precondition of an intron size
of at least 60bp.
In addition, 18 previously reported variants that are not disease
causing were correctly predicted not to cause erroneous splicing by all
five splice-site analysis tools, with the exception of one synonymous
variant that showed in four tools minor reduction scores of equal or
o7%. These variants are all confirmed to be non-disease causing,
because we now either established at the cDNA level that no erroneous
splicing occurred or that the variants were detected in healthy control
males or were published in dbSNP (see Table 1; see www.lovd.nl/
slc6a8).
Detection and classification of novel variants
Within the last decade, we have analyzed about 1900 individuals
(referred to our department because of, eg, MR, increased urinary
creatine/creatinine) by DNA sequence analysis of the SLC6A8 gene to
exclude/confirm creatine transporter defect. In this endeavor, we
identified 41 variants including 28 novel synonymous and intronic
variants that were not included in the dbSNP database and of which
their (non-) disease-causing nature needed to be established. All
were subjected to the five splice-site analysis tools. In total, three
novel pathogenic mutations (c.263-1G4C, c.778-2A4G and c.1596+
1G4A) were detected that were predicted to cause aberrant splicing
with reduction scores of 100% by at least three splice-site analysis tools
(Table 2). Twenty-seven variants showed no effect by all five tools. By
only one or two tools eight variants were predicted to decrease the
possibility of correct splicing by 10% or less. One synonymous
unclassified variant (c.780C4T) showed in three splice-site analysis
tools reduction scores that appear significant in terms of percentage,
but if the normal range is taken into account these differences
are considered minimal (eg, the score by the FruitFly tool shows a
decrease in 32% while the actual score decreases from 0.22 to 0.15 with
the range of low probability to high probability being 0–1.00). All
these variants were considered non-disease causing. Only one intronic
unclassified variant (c.777+4C4T) was predicted by all five splice-site
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Table 1 Proven pathogenic mutations and non-disease associated variants in SLC6A8
Location cDNA RNA Protein Controls Netgene2 Fruitfly
Splice
predictor Genscan W FSplice Path. Reference
01i c.262_262+1delinsTTa r.(spl?) p.(?) 0/280 1.0040 (100%) 0.9940.01 (99%) 0.9940 (100%) 57.0439.1 (31%) 12.440 (100%) +/+ Wilcken et al 21
01i c.2632A4G r.263_328del p.Gly88_Glu109del 0/280 0.9540 (100%) 0.6140 (100%) 0.9740 (100%) 21.945.9 (73%) 12.540 (100%) +/+ Schiaffino et al 20
05 c.912G4A r.772_912del p.Ile260_Gln304del 0/280 0.9940.80 (19%) 0.9540.67 (30%) 0.9940.88 (11%) 12.449.1 (27%) 11.646.0 (48%) +/+ Lion-Francois et al 18
06i c.1016+2T4C r.(spl?) p.(?) 0/280 0.9940 (100%) 0.9940 (100%) 0.9740 (100%) 18.2410.9 (40%) 10.1640 (100%) +/+ Rosenberg et al 2
07 c.1141G4C r.[1141G4C,
1129_1141del]
p.[Gly381Arg,
Val377GlyfsX15]
0/280 0.9940.90 (9%) 0.9240.17 (82%) 0.9940.90 (10%) 24.3418.7 (23%) 11.041.5 (86%) +/+ Hahn et al 17
09i c.1392+24_1393-30del r.[1392y]b p.[?] 0/280 NC NC NC NC NC +/+
10i c.1495+5G4C r.1393_1495del p.Gly465GlufsX12 0/280 0.9540.70 (26%) 0.9640 (100%) 0.9940.86 (13%) 17.9415.7 (12%) 11.041.5 (86%) +/+ Mancini et al 19
01i c.262+26T4C ND p.(¼) 6/280 NC NC NC NC NC / Rosenberg et al 2
02i c.394+88G4C ND p.(¼) rs6643763,
7/280
NC NC NC NC NC / Rosenberg et al 2
05 c.813C4T ND p.(¼) 4/280 NC NC NC NC NC / Clark et al 4
06i c.1016+9C4T r.¼ p.¼ 0/280 NC NC NC NC NC / Rosenberg et al 2
07i c.1141+37G4A r.¼ p.¼ rs2071028,
9/280
NC NC NC NC NC / Rosenberg et al 2
07i c.1141+87A4G r.¼ p.¼ rs41302172,
6/280
NC NC NC NC NC / Rosenberg et al 2
07i c.1142152_151del r.¼ p.¼ 0/280 NC NC NC NC NC / Rosenberg et al 2
07i c.114235G4A r.¼ p.¼ 2/280 NC NC NC NC NC / Rosenberg et al 2
08i c.1254+28C4T r.¼ p.¼ 0/280 NC NC NC NC NC / Rosenberg et al 2
08i c.125535G4A r.¼ p.¼ 0/280 NC NC NC NC NC / Rosenberg et al 2
09i c.139336G4A r.¼ p.¼ 1/280 NC NC NC NC NC / Rosenberg et al 2
10 c.1494C4T r.¼ p.¼ 1/280 0.9540.91 (4%) 0.9640.89 (7%) NC 17.9416.7 (7%) 11.0410.3 (6%) / Rosenberg et al 2
10i c.149618C4T r.¼ p.¼ 0/280 NC NC NC NC NC / Rosenberg et al 2
11i c.1596+21G4A r.¼ p.¼ 0/280 NC NC NC NC NC / Rosenberg et al 2
12 c.1678A4G ND p.(Met560Val) 1/280 NC NC NC NC NC / Rosenberg et al 2
and Clark et al 4
12i c.1767+15C4T r.¼ p.¼ 0/280 NC NC NC NC NC / Rosenberg et al 2
12i c.1767+32C4A r.¼ p.¼ 0/280 NC NC NC NC NC / Rosenberg et al 2
12i c.176882G4C ND p.(¼) 1/280 NC NC NC NC NC / Rosenberg et al 2
aThis mutation arose de novo.
br.[1392_1393ins1392+1_1393-1;1392+24_1393-30del, 1393_1495del].
Location refers to the intron (i) or exon (two digits) number in which the variant was found. In the upper panel the proven pathogenic variants are denoted. The lower panel includes both intronic
and synonymous variants.
ND, not performed. NC: no change. Variant did not influence the predicted score compared with the canonical site.
Path.: reported and concluded pathogenicity. +: pathogenic; : no known pathogenicity.
r.(spl?): the variant is expected to affect splicing; however, no further mRNA analysis is performed.
cDNA denotation is based on the reference sequence NM_005629.3, where +1 corresponds to the first nucleotide of the initiation codon. All variants are annotated according to the guidelines of
Den Dunnen and Antonarakis
(http://www.genomic.unimelb.edu.au/mdi/mutnomen/).
Table 2 Twenty-eight novel intronic variants and 13 previously reported unclassified variants in SLC6A8
Location cDNA Deduced effect Netgene2 Fruitfly Splice predictor Genscan W FSplice Path. Reference
01i c.262+65G4A p.(¼) NC NC NC NC NC ?/?
01i c.263-1G4C r.263_325del 0.9540 (100%) 0.9340.32 (66%) 0.9740 (100%) 21.945.9 (73%) 12.540 (100%) +/+
02 c.306A4G p.(¼) NC NC NC NC NC ?/?
02i c.394+52C4T p.(¼) NC NC NC NC NC ?/?
02i c.394+66C4A p.(¼) NC NC NC NC NC ?/?
02i c.394+72C4A p.(¼) NC NC NC NC NC ?/?
02i c.394+88G4A p.(¼) NC NC NC NC NC ?/?
03 c.495C4T p.(¼) NC NC NC 33.3432.8 (2%) NC ?/?
03 c.603C4T p.(¼) NC NC NC NC NC ?/? Clark et al 4
03i c.644+9G4A p.(¼) NC NC 0.8540.79 (7%) NC NC ?/?
04i c.777+4C4Ta p.(¼) 0.9140.82 (10%) 0.6140.47 (23%) 0.9440.92 (2%) 7.846.6 (15%) 9.648.7 (10%) /
04i c.7782A4G r.(spl?) 1.0040 (100%) 0.2240 (100%) SND 12.447.7 (38%) 3.340 (100%) +/+
05 c.780C4T p.(¼) 1.0040.96 (4%) 0.2240.15 (32%) NC NC 3.342.67 (20%) ?/? Clark et al 4
05 c.856C4T p.(¼) NC NC NC NC NC /
05i c.91340T4C p.(¼) NC NC NC NC 10.049.2 (9%) ?/?
06i c.1016+41_46del p.(¼) 0.9940.96 (3%) NC NC NC NC ?/?
06i c.1016+41_45dup p.(¼) NC NC NC NC NC ?/? Clark et al 4
06i c.101738C4G p.(¼) NC NC NC NC 10.2410.0 (2%) ?/? Clark et al 4
07i c.1141+18G4A p.(¼) NC NC NC NC NC ?/?
07i c.1142130C4T p.(¼) NC NC NC NC NC ?/? Clark et al 4
07i c.1142122C4T p.(¼) NC NC NC NC NC ?/?
07i c.1142100G4A p.(¼) NC NC NC NC NC ?/?
07i c.114298C4A p.(¼) NC NC NC NC NC ?/? Rosenberg et al 2
07i c.114219G4A p.(¼) NC NC NC NC NC ?/?
08 c.1162G4A p.(Ala388Thr) NC NC NC NC NC /
08i c.1254+39G4T p.(¼) NC NC 0.9240.89 (3%) NC NC ?/? Clark et al 4
08i c.1254+54C4T p.(¼) NC NC NC NC NC ?/? Clark et al 4
09i c.1392+12G4T p.(¼) NC NC NC NC NC ?/?
09i c.1392+31T4C p.(¼) NC NC NC NC NC ?/? Clark et al 4
10 c.1416G4A p.(¼) NC NC NC NC NC / Rosenberg et al 2
10 c.1437C4T p.(¼) NC NC NC NC NC ?/? Clark et al 4
10i c.14968C4T p.(¼) NC NC NC NC NC ?/?
10i c.14967G4A p.(¼) 1.0040.96 (4%) 0.7240.67 (7%) NC NC NC ?/?
10i c.14965C4T p.(¼) NC NC 0.8640.81 (6%) NC NC ?/? Clark et al 4
11i c.1596+1G4A r.(spl?) 0.9540 (100%) 1.0040 (100%) 0.9940 (100%) 14.1940 (100%) 11.9840 (100%) +/+
11i c.1596+24_1597-41dup p.(¼) NC NC NC NC NC ?/?
11i c.1596+28C4T p.(¼) NC NC NC NC NC ?/?
11i c.159720C4T p.(¼) NC NC NC NC NC ?/?
12 c.1629G4A p.(¼) NC NC 0.5740.55 (4%) 27.9425.3 (9%) NC ?/?
12 c.1662G4A p.(¼) NC NC NC NC NC ?/? Clark et al 4
12i c.1767+20C4T p.(¼) NC NC NC NC NC ?/?
aThis variant was cloned into a minigene. Overexpression studies indicated that this variant does not affect splicing.
None of these variants, including 3 pathogenic mutations and 13 previously reported variants were detected in 280 control alleles.
Location refers to the intron (i) or exon (two digits) number in which the variant was found. /
NC: no change (ie, the variant did not influence the predicted score compared with the canonical site)
SND: site not detected. The canonical donor or acceptor site is not recognized as a naturally occurring site by this splice-site analysis tool.
Path.: reported/concluded pathogenicity. : no known pathogenicity; ?: probably no pathogenicity; ?: unknown; +?: probably pathogenic; +: pathogenic.
Deduced effect: brackets indicate that the variant has not been tested at the mRNA level; r.(spl?): the variant is expected to affect splicing; p.(¼), no effect predicted, but not tested at the mRNA level.
cDNA denotation is based on the reference sequence NM_005629.3, where +1 corresponds to the first nucleotide of the initiation codon. All variants are annotated according to the guidelines of
Den Dunnen and Antonarakis
(http://www.genomic.unimelb.edu.au/mdi/mutnomen/).
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analysis tools to reduce the probability of the canonical donor site of
exon 4 (Table 2) by 10, 2, 23, 10 and 15% compared with the
canonical donor site score. cDNA was not available from this patient
and thus this variant was studied by overexpression of a minigene
(ie, a genomic SLC6A8 segment containing the c.777+4C4T variant).
Both overexpression of the wild-type minigene as well as the
mutant minigene in SLC6A8-deficient primary fibroblasts showed
normal splicing as detected by RT-PCR and sequence analysis.
This is in contrast to the positive control minigene that contained the
c.777+2T4A mutation and resulted in skipping of exon 4 (Figure 1).
Five novel SLC6A8-deficient patients
The first case (patient I) was a young female (DOB January 1993)
born at term following a normal pregnancy and delivery with normal
weight, length and head circumference. From the age of 2, she deve-
loped a behavior disturbance and was assessed by a pedopsychiatric
institution that also diagnosed mild MR. At age 14, she was affected
with auditory hallucinations and the diagnosis of chronic hallucina-
tory psychosis was made. Her cognitive impairment was stable with
conserved language capacities and social contact, no motor impair-
ment and no specific neurological signs. Her total IQ was tested at 45
(verbal: 61, reason: 45, memory: 53; and working velocity: 66). A brain
H-MRS was performed which showed a reduced cerebral creatine
level with a normal appearance to choline and N-acetylaspartic acid
(Figure 2). Urinary creatine levels were within the upper normal
range. Plasma creatine was determined twice resulting in values of
39.9mmol/l and 75.4mmol/l (normal 30–124mmol/l). Genomic DNA
sequencing revealed a c.263-1G4C mutation. This mutation arose de
novo. Somatic mosaicism was not detected in her parents’ DNA by
both DNA analysis and the use of DHPLC (Figure 3). mRNA isolated
from PAX tubes, followed by cDNA synthesis showed approximately
Figure 1 RT-PCR results of spliced products after transfection of the
minigenes in SLC6A8-deficient fibroblasts. SLC6A8-deficient fibroblast
were transfected with a minigene, containing an exon 3 to 7 fragment of
SLC6A8 with either a wild-type sequence, the c.777+2T4A transversion or
the c.777+4C4T variant. Cells were harvested and RNA was isolated using
the Promega RNA Isolation Kit. Subsequent RT-PCR of the wild-type and
the c.777+4C4T minigene transfected fibroblasts resulted in an amplicon of
384bp, indicating the variant not to cause aberrant splicing. The positive
control (c.777+2T4A transfectants) resulted in a 251bp amplicon.
Sequencing analysis showed that exon 4 was skipped in the 251bp amplicon.
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Mother
Father
Patient I10
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Figure 3 Patient I with a c.263-1G4C mutation in the SLC6A8 gene.
Somatic mosaicism for the c.263-1G4C mutation was not detected in both
parents of patient I. The DHPLC elution profile of the exon 2 amplicon
of EDTA blood DNA of patient I with a c.263-1G4C variant in SLC6A8
including her parents and a male control. At the retention time of the
heteroduplex peak clearly visible with the patient, no peak is visible with the
parents, indicating both are not somatic mosaic for the mutation.
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Figure 2 Proton MRS of the brain of an index girl with SLC6A8 deficiency
(patient I). A proton MRS was performed on a 14-year-old girl with mild
mental retardation. Creatine (Cr) was found to be reduced with a normal
appearance to choline (Cho) and N-acetylaspartic acid (NAA). Subsequent
genomic DNA sequencing revealed a pathogenic c.263-1G4C mutation,
which confirmed the diagnosis of SLC6A8 deficiency.
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90% r.263_325del (p.Gly88_Leu108del) and 10% wild-type product.
The X-inactivation was studied in blood with the analysis of
HhaI digested and undigested DNA followed by PCR of the highly
polymorphic CAG repeat of the androgen receptor gene and showed
a 90:10 pattern. Also, fibroblasts incubated with a physiological
concentration of creatine (25mM) showed no uptake. All these findings
combined confirmed creatine transporter deficiency.
The second case (patient II) was a 7-year-old male with epilepsy,
expressive language difficulties and a movement disorder. He was
tested for mutations in SLC6A8 after H-MRS of the brain revealed a
diminished creatine peak with a normal appearance to NAA and
choline and urinary analysis showed an increased Cr/Crn value. This
resulted in the detection of a hemizygous c.778-2A4G variant. His
brother (patient III), currently 10 years old, showed a similar clinical
phenotype with an increased urinary Cr/Crn value and absence of
cerebral creatine. He was also found to be hemizygous for this variant
while his mother was proven to be heterozygous.
The fourth patient (patient IV) was a young male with a reduced
cerebral creatine level measured by H-MRS. Further investigation
resulted in the detection of a c.1596+1G4A variant, which was also
found to be heterozygous in DNA from his mother.
The fifth patient (patient V) was unmistakably diagnosed with
SLC6A8 deficiency at the age of 6 years. The patient suffered from
moderate MR and severe language delay. Quantitative localized single
voxel magnetic resonance spectroscopy was performed over the basal
ganglia and revealed a markedly diminished creatine level with a
normal appearance to choline. Urinary analysis revealed a creatine/
creatinine value of 1.7 (normal 0.017–0.72).13 The creatine uptake
ability of the patients’ fibroblasts was significantly decreased in
comparison with control cells when incubated at a physiological
creatine concentration of 25mM. Moreover, the mutation could not
be detected in the DNA of the mother and is therefore considered
de novo. At the cDNA level, two erroneous transcripts were revealed
(r.[1392_1393ins1392+1_1393-1;1392+24_1393-30del,1393_1495del])
(Figure 4). This conclusively classified the c.1392+24_1393-30del
mutation as the pathogenic event. Also, the same de novo mutation
was detected in an unrelated patient.14
LOVD database
In total, the LOVD database of SLC6A8 lists 44 SLC6A8-deficient
families, with a total of 43 mutations. Of these, 38 are proven
pathogenic (+/+), whereas 5 others are presumed to be pathogenic
(+?/+?). The latter are all missense variants, which have not been
investigated by overexpression studies yet.15
The database (Figure 5) provides detailed information on the
nature of the variants, but also exon–intron location of the DNA
change (both according to current nomenclature and as published),
RNA change and protein change. To all variants a unique database
number is assigned. The column ‘variant remarks’ provides a detailed
description on the nature of the variant. The final conclusion is
presented in the first column ‘path.’ in which the first sign provides
the conclusion of the report and the second one that of the curator
(eg, +/+ meaning confirmed pathogenic). Other columns include
detailed information on the variant origin, reference, template, tech-
nique, frequency, disease status, patient remarks, times reported,
gender, geographic origin and ethnic origin. Moreover, clinical symp-
toms are continuously archived (non-public). The database is an
excellent tool to get an up-to-date overview of the type of mutations,
the frequency of specific variants and more details. This data can be
found in the different tabs by any user, but an advanced search
function is also available. Researchers or clinicians who are interested
in the nature of a specific variant can use the database to search if the
variant has been detected in other patients. This information may have
been published in reports or on the website only, but also may include
unpublished variants, which have not yet been made public. The latter
allows contact between clinicians even if the data are not publicly
released. All scientists/clinicians are invited to submit their data to the
database. The identity of the submitter is included in the database.
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Figure 4 Schematic representation of the c.1392+24_1393-30del variant in SLC6A8. The c.1392+24_1393-30del variant was found in two independent
patients and occurred de novo in both cases. In the patients’ DNA a hemizygous variant, c.1392+24_1393-30del, was found (upper pane). mRNA analysis
showed that this variant affects splicing and results in different splice products, r.[1392_1393ins1392+1_1393-1;1392+24_1393-30del, 1393_1495del]
(lower pane), resulting in SLC6A8 deficiency. For the second patient see Hathaway et al.14 This variant is annotated according to the guidelines of
Den Dunnen and Antonarakis (http://www.genomic.unimelb.edu.au/mdi/mutnomen/).
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DISCUSSION
In this study, the nature of 67 intronic and synonymous variants has
been studied by free web-based splice-site analysis tools. These have
been characterized and are all being included in a newly developed
LOVD database. In addition, all previously published mutations are
included in this database as well. This is of high relevance for
researchers and clinicians who detect difficult to interpret variants
in the SLC6A8 gene. In an ideal diagnostic setup, an unclassified
variant is further investigated at the mRNA, protein and/or functional
level to confirm/exclude its pathogenic nature. However, in diagnostic
laboratories time is usually limited and proper materials are often not
available. Therefore, alternative methods are warranted for variant
classification such as frequently used splice-site analysis tools, which
predict the possible effect on RNA splicing of a variant based on
known and computed conserved splicing sequences. Here we demon-
strate that the use of five splice-site analysis tools, indeed is very
helpful for proper classification.
In total, 24 out of 25 (96%) variants were properly classified by the
combined use of the five tools. The importance of using more than
one splice-site analysis tool is illustrated by the fact that four out
of seven proven pathogenic mutations were not predicted to
have a strong effect (ie, 90% or higher reduction) by one or more
of the individual analysis tools, whereas the combined data of all
the tools clearly predicted erroneous splicing for six of these variants
(Table 1). In one case, only one tool predicted a reduction in the
probability of correct splicing. The fact that this ‘missed’ mutation
(c.1392+24_1393-30del) comprises an intronic deletion of 24 bp out
of a 76bp intron, easily explains this omission as none of the
five splice-site analysis tools have intron size as a parameter. This
caveat is an important finding for diagnostic laboratories that
encounter this specific type of mutations (eg, deletions, insertions in
small introns). We demonstrated that this deletion indeed results in
erroneous spliced transcripts (r.[1392_1393ins1392+1_1393-1;1392+24_
1393-30del,1393_1495del]), (Hathaway et al,14 this study).
Figure 5 Screenshot of the newly developed LOVD/SLC6A8 database. The currently known variants and pathogenic mutations of SLC6A8 are described in
the newly developed LOVD database including the corresponding clinical data. Search queries can be performed for many parameters (ie, specific variant,
exon number, biochemical findings). In order to submit variants it is required to log in, after which the variants will be checked for correctness and
completeness by the curator.
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In 17 out of 18 proven variants, no change in prediction scores was
detected by any of the five tools. Only one variant that was proven not
to interfere with proper splicing, had a reduced score of 7% or less
compared with the canonical site by four of the five tools. Owing to
this variant, we arbitrarily decided to only consider variants for further
molecular workup if at least three tools predicted a mild effect
(10o480%), or if one or two tools predicted a significant effect
(480%). In addition, we took into account the prediction score of
the wild-type splice site. Thus, a 50% reduction of a canonical site
with a 0.99 score is more likely to have an effect on splicing than a 50%
reduction in a splice site with a much weaker score of for instance 0.22.
Utilizing these criteria, we analyzed the potential effect of 41
unclassified variants on the SLC6A8 mRNA with the use of these
five splice-site analysis tools. This resulted in the identification of
three pathogenic mutations (c.263-1G4C, c.778-2A4G and
c.1596+1G4A), and 38 variants that have no apparent relation with
creatine transporter deficiency. The effect on splicing for two of the
three novel pathogenic mutations could not be confirmed at the
cDNA level. However, given the fact that all three mutations affect the
donor or acceptor splice-site, all were classified as pathogenic. Patho-
genicity was in excellent agreement with the fact that the mutations
were not detected in 280 control chromosomes, the biochemical
findings (increased urinary Cr/Crn) and/or reduced cerebral creatine
detection by H-MRS.
Interestingly, one novel mutation (c.263-1G4C) was found in a
girl, who according to our knowledge is the first reported index girl
affected with SLC6A8 deficiency. The girl was not correctly diagnosed
until the age of 14 when a brain H-MRS revealed a reduced cerebral
creatine level. This led to DNA analysis that resulted in the discovery
of the pathogenic c.263-1G4C mutation. Additional investigations
revealed a urinary creatine to creatinine ratio within the normal range
as well as normal values for plasma creatine. The discrepancy between
the urinary, plasma and cerebral creatine levels is possibly caused by
variation of the X-inactivation pattern in different tissues, which was
shown to be skewed in blood of this patient.
In a recently described cohort of female relatives who were hetero-
zygous for a pathogenic mutation in SLC6A8, it was shown that
symptoms of SLC6A8 deficiency (eg, MR, learning difficulties and
constipation) can occur in female heterozygotes. However, it should
be noted that the level of biochemical markers (urinary creatine to
creatinine ratio and/or cerebral creatine) usually overlap with that of
normal controls. This is in concordance with the clinical and bio-
chemical findings of the above mentioned female index patient and
confirms the recommendation of screening for mutations in SLC6A8
in females with (mild) MR/psychiatric disorders as this method
appears to be the most sensitive and specific test.16
In only 1 of the 38 UVs, mild reduction values of the probability
scores were detected by all five splice-site analysis tools. Unfortunately,
it was not possible to obtain additional material of the patient to
isolate mRNA, and clinically it was also not possible to exclude/
confirm SLC6A8 deficiency. We therefore selected this variant
(c.777+4C4T) for overexpression studies of a minigene containing
the variant. These studies revealed no aberrant splicing and therefore
this variant is also considered non-pathogenic.
After evaluating the results of the splice-site analysis tools reported
in this study, we defined our criteria for the analysis of SLC6A8. If at
least three out of five splice-site analysis tools predict a reduction of
410% or one out of five predicts a reduction of 80% of the site score
compared with the canonical site, further research is warranted.
However, a critical view needs to be kept which is illustrated by the
fact that in our study 1 out of the 10 proven pathogenic mutations
would have escaped proper identification. The c.1392+24_1393-30del
mutation was not recognized by the overall prediction score of all five
splice-site analysis tools. It is noteworthy that these scores do not
include composition, size and branch site of the intron as parameters.
One exception is Splice predictor, which does have additional intron-
dependent scores, namely rho and gamma. Unfortunately, these scores
are not calculated and set at zero when an intron is smaller than 60bp,
therefore making it difficult to deduce the actual reduction with this
variant as the deletion leads to a 52 bp intron. This of course reduces
the reliability of these scores because naturally occurring introns can
have sizes of 60 bp and less.
In conclusion, splice-site analysis tools are very important in the
process of classifying novel variants. For definite classification of novel
variants outside the canonical donor and acceptor sites, in vitro
experimentation, either with mRNA analysis or with the use of a
minigene (if no additional material is available), is an essential
procedure.
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